Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02947113 | Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC(HYPOLAN) | withdrawn | Phase 2 | 0 | The Netherlands Cancer InstituteOTHER | 0 | Nov 30, 2017 | clinicaltrials |
| NCT02405910 | Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC. | withdrawn | Phase 2 | 0 | West Virginia UniversityOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT02876081 | Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex(THEN) | withdrawn | Phase 2 | 0 | Fondation Hôpital Saint-JosephOTHER | 1 | Sep 11, 2017 | clinicaltrials |
| NCT02924233 | Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Symphogen A/SINDUSTRY | 0 | Aug 28, 2017 | clinicaltrials |
| NCT02425072 | NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | John VillanoOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT02639234 | Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Gradalis, Inc.INDUSTRY | 1 | Jul 31, 2017 | clinicaltrials |
| NCT03042013 | A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study | withdrawn | Phase 2 | 0 | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Jul 11, 2017 | clinicaltrials |
| NCT02495636 | Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT02735850 | Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR)(ImmunoSABR) | withdrawn | Phase 2 | 0 | Maastricht Radiation OncologyOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01640847 | MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases | withdrawn | Phase 2 | 0 | ImunonINDUSTRY | 0 | Feb 7, 2017 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT01179269 | Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Loyola UniversityOTHER | 0 | Oct 12, 2016 | clinicaltrials |
| NCT02522910 | An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | withdrawn | Phase 1 / Phase 2 | 0 | Yonsei UniversityOTHER | 0 | Aug 10, 2016 | clinicaltrials |
| NCT02673814 | Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer | withdrawn | Phase 2 | 0 | Peregrine PharmaceuticalsINDUSTRY | 0 | Aug 1, 2016 | clinicaltrials |
| NCT02152059 | A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy | withdrawn | Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT02705339 | Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | May 17, 2016 | clinicaltrials |
| NCT02651506 | Electromagnetic Navigational Bronchoscopy Vs. Transthoracic Needle Biopsy for the Sampling of Peripheral Lung Nodules | withdrawn | Phase 2 | 0 | St. Joseph's Healthcare HamiltonOTHER | 0 | May 12, 2016 | clinicaltrials |
| NCT02536495 | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Erin BertinoOTHER | 0 | Oct 30, 2015 | clinicaltrials |
| NCT00768131 | A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel | withdrawn | Phase 2 | 0 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00755157 | Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | University Hospital of CreteOTHER | 1 | Oct 7, 2015 | clinicaltrials |
| NCT01184287 | A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Tamir Biotechnology, Inc.INDUSTRY | 1 | Sep 2, 2015 | clinicaltrials |
| NCT01928160 | Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib | withdrawn | Phase 2 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Jul 13, 2015 | clinicaltrials |
| NCT00697060 | A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | AmpliMed CorporationINDUSTRY | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00903942 | Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | University of RochesterOTHER | 1 | Apr 27, 2015 | clinicaltrials |
| NCT01048983 | Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 5, 2015 | clinicaltrials |
| NCT02297425 | A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer | withdrawn | Phase 2 | 0 | PfizerINDUSTRY | 0 | Jan 12, 2015 | clinicaltrials |
| NCT01336543 | Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | Syed JafriOTHER | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01913067 | Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC(CRANIAL) | withdrawn | Phase 2 | 0 | Jules Bordet InstituteOTHER | 1 | Jul 24, 2014 | clinicaltrials |
| NCT00112060 | A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 1 / Phase 2 | 0 | Spectrum Pharmaceuticals, IncINDUSTRY | 2 | Mar 31, 2014 | clinicaltrials |
| NCT01256203 | Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light | withdrawn | Phase 2 | 0 | Pinnacle Biologics Inc.INDUSTRY | 0 | Mar 4, 2014 | clinicaltrials |
| NCT00256841 | Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy | withdrawn | Phase 1 / Phase 2 | 0 | Clinical Oncology Research AssociatesOTHER | 1 | Jan 29, 2014 | clinicaltrials |
| NCT01533727 | CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Dec 9, 2013 | clinicaltrials |
| NCT01504542 | Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Heat BiologicsINDUSTRY | 1 | Nov 21, 2013 | clinicaltrials |
| NCT01674738 | TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV(SELECT-A) | withdrawn | Phase 2 | 0 | Aktion Bronchialkarzinom e.V.OTHER | 0 | Oct 11, 2013 | clinicaltrials |
| NCT01728181 | A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation | withdrawn | Phase 1 / Phase 2 | 0 | University of UtahOTHER | 0 | Jul 25, 2013 | clinicaltrials |
| NCT00916669 | A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC) | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | May 8, 2013 | clinicaltrials |
| NCT00268255 | Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Apr 16, 2013 | clinicaltrials |
| NCT00386555 | A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel. | withdrawn | Phase 2 | 0 | Arog Pharmaceuticals, Inc.INDUSTRY | 0 | Aug 9, 2012 | clinicaltrials |
| NCT00048087 | Iressa/Docetaxel in Non-Small-Cell Lung Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2012 | clinicaltrials |
| NCT00472771 | INNO-206 in Patients With Small Cell Lung Cancer (SCLC) | withdrawn | Phase 2 | 0 | CytRxINDUSTRY | 1 | Feb 9, 2012 | clinicaltrials |
| NCT01449357 | Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors | withdrawn | Phase 2 | 0 | GenmabINDUSTRY | 0 | Oct 10, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Nov 30, 2017source: clinicaltrials